share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4：持股變動聲明
SEC announcement ·  03/22 17:48
Moomoo AI 已提取核心訊息
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, has been reported to engage in a transaction involving the company's stock. The action took place on March 20, 2024. However, the announcement did not disclose the type of action, the status, the number of shares involved, the nature of the shares, the transaction price, or the post-transaction shareholding details. Without these specifics, the impact of this event on CRISPR Therapeutics' stock remains unclear to investors.
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, has been reported to engage in a transaction involving the company's stock. The action took place on March 20, 2024. However, the announcement did not disclose the type of action, the status, the number of shares involved, the nature of the shares, the transaction price, or the post-transaction shareholding details. Without these specifics, the impact of this event on CRISPR Therapeutics' stock remains unclear to investors.
據報道，CRISPR Therapeutics總法律顧問兼秘書詹姆斯·卡辛格參與了一項涉及該公司股票的交易。該行動於 2024 年 3 月 20 日進行。但是，該公告沒有透露行動類型、狀態、所涉股票數量、股票性質、交易價格或交易後的持股細節。如果沒有這些細節，投資者尚不清楚這一事件對CRISPR Therapeutics股票的影響。
據報道，CRISPR Therapeutics總法律顧問兼秘書詹姆斯·卡辛格參與了一項涉及該公司股票的交易。該行動於 2024 年 3 月 20 日進行。但是，該公告沒有透露行動類型、狀態、所涉股票數量、股票性質、交易價格或交易後的持股細節。如果沒有這些細節，投資者尚不清楚這一事件對CRISPR Therapeutics股票的影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息